Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis - PubMed
4 days ago
- #Diroximel Fumarate
- #Multiple Sclerosis
- #Anti-CD20
- Comparative study on severe infection risk and annualized relapse rate (ARR) between diroximel fumarate (DRF) and anti-CD20 monoclonal antibodies in MS patients.
- DRF-treated patients showed lower severe infection rates at 12 and 24 months compared to anti-CD20-treated patients, with significant differences in younger patients.
- COVID-19-related severe infections were significantly lower in DRF-treated patients.
- No significant difference in ARR was observed between DRF and anti-CD20-treated groups.
- Study highlights the need for more real-world data on disease-modifying therapies (DMTs) efficacy and safety, especially in aging MS patients.